Takeda Pharmaceutical Co. (TAK)
(Delayed Data from NYSE)
$13.17 USD
+0.14 (1.07%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $13.17 0.00 (0.00%) 7:58 PM ET
1-Strong Buy of 5 1
A Value F Growth A Momentum C VGM
Price, Consensus and EPS Surprise
TAK 13.17 +0.14(1.07%)
Will TAK be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TAK based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TAK
Down -6.19% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
Down -5.9% in 4 Weeks, Here's Why Takeda Pharmaceutical Co. (TAK) Looks Ripe for a Turnaround
TAK: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Takeda Pharmaceutical Co. (TAK) Rating Upgrade to Strong Buy
TAK or CTLT: Which Is the Better Value Stock Right Now?
Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?
Other News for TAK
Hutchmed notes CHMP's positive opinion for fruiquintinib approval
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
Takeda announces CHMP opinion recommending approval of fruquintinib
Hutchmed announces positive CHMP opinion for fruquintinib